AbbVie Beats Q1 2026 Earnings, Raises Full-Year Forecast
AbbVie (ABBV) reported Q1 2026 earnings that beat analyst estimates, fueled by strong sales of Skyrizi and Rinvoq which together generated over $6.6 billion, far outpacing Humira's $688 million. The company also raised its full-year forecast.
Key Numbers
AbbVie (ABBV) reported first-quarter 2026 results that exceeded analyst expectations, driven by robust growth of its newer drugs Skyrizi and Rinvoq. The two drugs generated combined sales of more than $6.6 billion, significantly outpacing Humira's $688 million. The company also raised its full-year guidance.
Key Financial Results
| Metric | Q1 2026 | YoY Change (Est.) |
|---|---|---|
| Skyrizi & Rinvoq Sales | > $6.6B | Strong growth |
| Humira Sales | $688M | Sharp decline |
| Total Revenue | Not yet disclosed | — |
| Net Income | Not yet disclosed | — |
| EPS | Not yet disclosed | — |
Highlights from the Release
AbbVie stated that the strong performance of Skyrizi and Rinvoq is effectively compensating for the decline in Humira sales, which has lost patent protection and faces biosimilar competition. Demand for these two drugs remains high in indications such as rheumatoid arthritis and psoriasis.
Future Guidance
AbbVie raised its full-year 2026 outlook, expecting revenue growth driven by its new product portfolio. Specific guidance figures have not yet been released.
Stock Impact
The earnings beat and raised guidance are expected to support ABBV shares in upcoming trading sessions, as investor confidence shifts toward the company's new growth drivers.
What This Means for Investors
This report highlights AbbVie's successful strategy in offsetting Humira's decline with new products. Investors will be watching the company's ability to sustain this growth amid competition.
Frequently Asked Questions
Found this useful? Share it